CytomX Therapeutics (CTMX) Change in Receivables (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Change in Receivables came in at -$1.4 million in Q1 2026, down 19.18% YoY from -$1.7 million in Q1 2025, and down 455.99% on a QoQ basis from $384000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Change in Receivables (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Change in Receivables data on file, last reported at -$1.4 million in Q1 2026.
- Quarterly Change in Receivables fell 19.18% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (up 88.33% YoY) and the FY2025 annual result came in at -$1.1 million, down 231.31% from the prior year.
- Change in Receivables eased to -$1.4 million in Q1 2026, from $384000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $34.2 million in Q4 2022 to a low of -$34.9 million in Q1 2023.
- A 5-year average of -$8470.6 and a median of $232000.0 in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables jumped 35368.04% — and 2023, when it tumbled 15141.38%.
- Tracing CTMX's Change in Receivables over 5 years: stood at $34.2 million in 2022, then tumbled by 97.04% to $1.0 million in 2023, then tumbled by 124.58% to -$249000.0 in 2024, then surged by 254.22% to $384000.0 in 2025, then plunged by 455.99% to -$1.4 million in 2026.
- The last three Change in Receivables figures came in at -$1.4 million (Q1 2026), $384000.0 (Q4 2025), and -$240000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 36.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.85 Mn |
| Jun 30, 2026 | 36.85 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Dec 31, 2025 | 384,000.00 |
| Dec 31, 2025 | 384,000.00 |
| Sep 30, 2025 | -240,000.00 |
| Sep 30, 2025 | -240,000.00 |
| Jun 30, 2025 | -87,000.00 |
| Jun 30, 2025 | -87,000.00 |
| Mar 31, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.15 Mn |
| Dec 31, 2024 | -249,000.00 |
| Dec 31, 2024 | -249,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Jun 30, 2024 | -10.40 Mn |
| Jun 30, 2024 | -10.40 Mn |
| Mar 31, 2024 | 9.75 Mn |
| Mar 31, 2024 | 9.75 Mn |